Plasma 7-Hydroxymethotrexate Levels Versus Methotrexate to Predict Delayed Elimination in Children Receiving High-Dose Methotrexate
Authors:
- 1 February 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 40 (1) , 76-83
Abstract
Background: The aim of this study was to investigate the correlation between 7-hydroxymethotrexate (7-OHMTX) and creatinine and to evaluate the predictive value of 7-OHMTX levels on delayed elimination at 24 and 48 hours. In addition, differences in methotrexate (MTX), 7-OHMTX levels, and MTX metabolism using the ratio MTX/7-OHMTX were determined according to age. Methods: The authors included a total of 106 cycles, corresponding to 33 patients (mean age: 9.8 years, range: 2–18 years) suffering from acute lymphoblastic leukemia, non-Hodgkin lymphoma and osteosarcoma and receiving high-dose MTX (HD-MTX). Plasma MTX, 7-OHMTX, and creatinine at T24 and T48 hours were measured. Results: Children older than 14 years had significantly higher MTX levels at T48 hours (1.25 versus 0.5 μmol/L, P < 0.05) and a higher MTX/7-OHMTX ratio (0.63 versus 0.20, P < 0.05) than children younger than 6 years. Plasma 7-OHMTX at T24 and T48 hours was positively correlated with serum creatinine and creatinine ratio at T24 and T48 hours. MTX levels provided a better specificity and sensitivity at both 24 and 48 hours than 7-OHMTX to predict delayed MTX elimination. A MTX threshold close to 0.83 μmol/L at T48 hours improved specificity from 58% to 82% and keeps sensitivity at 100%. The authors identified a cut-off at 65 μmol/L for MTX at T24 hours with a good sensitivity (75%) and specificity above 50%. Conclusions: These results confirm the concentration-dependent nephrotoxicity of 7-OHMTX. Children older than 14 years old had a higher MTX levels at 48 hours and a higher MTX/7-OHMTX ratio, suggesting a faster metabolism in younger children. This study identified a higher and more specific MTX threshold at T48 hours compared to those currently used, and a new threshold at T24 hours.Keywords
This publication has 30 references indexed in Scilit:
- Niveau de preuve du suivi thérapeutique pharmacologique du méthotrexate au décours de son administration à haute-doseTherapies, 2010
- Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical EffectsJournal of Clinical Oncology, 2009
- Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 StudyJournal of Clinical Oncology, 2008
- Drug-induced crystal nephropathy: an updateExpert Opinion on Drug Safety, 2008
- High‐dose methotrexate therapy of childhood acute lymphoblastic leukemia: Lack of relation between serum methotrexate concentration and creatinine clearancePediatric Blood & Cancer, 2004
- Schwere renale Methotrexat-Ausscheidungsstörung nach Hochdosis-TherapieKlinische Padiatrie, 1994
- Comparative study on the pharmacokinetics of 7‐hydroxy‐methotrexate after administration of methotrexate in the dose range of 0.5‐33.6 g/m2 to children with acute lymphoblastic leukemiaMedical and Pediatric Oncology, 1990
- Pharmacokinetics of Anticancer Drugs in ChildrenClinical Pharmacokinetics, 1987
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977
- 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate.Journal of Clinical Investigation, 1976